Navigation Links
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
Date:10/28/2009

ope.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment ahead of schedule for TB-402. We believe that based on its novel profile, TB-402 could be an important new entrant into the anticoagulant therapy market. Given the size of commercial opportunity for TB-402 and the sales reach that will be needed to engage with all of the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent. We very much look forward to announcing the results from this study in Q2 next year."

Svein Mathisen, CEO of BioInvent, also commented, "At BioInvent, we are proud to have maintained excellent momentum in the Phase II study of TB-402, which is on track to be completed ahead of schedule. We look forward to announcing the results of the study in Q2 next year. Our expectation is that the ongoing clinical development will underpin the product profile as a safe and effective long acting new anticoagulant."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 600,000 patients are treated for venous thromboembolisms such as DVT or pulmonary embolism (PE) each year.[1] Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.[2]

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.[3] Patients undergoing hip replacement or knee surgery are particularly at risk of developing DVT and all patients are therefore treated with anticoagulants prophylactically in order to reduce the risks of blood clots. The annual sales of anticoagulants
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
2. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
3. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
4. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
5. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
6. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
7. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
8. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Delcath Systems, Inc. Completes Phase III Study Enrollment
11. Abbott Completes Visiogen Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 Regado Biosciences, Inc. ... on the Phase 3 clinical development of Revolixys™ Kit ... drug system, today announced that it will hold a ... 12, 2014, at 8:30 a.m. EDT to discuss its ... Interested participants and investors may access the conference ...
(Date:7/29/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... healthcare conferences during the third quarter, the 2014 Avondale ... Healthcare 2014 Conference.  Alexza,s corporate presentation will be webcast ... each event are below: , 2014 Avondale ... Boston , MA.  The format is ...
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... , MIAMI , July 21 Understanding ... patient resources. That,s why Puerto Rican actress, author and mother ... partnered with the Asthma and Allergy Foundation of America (AAFA) ... new Spanish asthma education web resource to help patients learn ...
... Trinity Orthopedics LLC, a medical device company that develops and markets ... a Notice of Allowance from the U.S. Patent and Trademark Office for ... posterior fixation system in the United States under the ReStor ... "Recent clinical studies ...
Cached Medicine Technology:Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 2Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 3Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 4Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 5Latina Actress and Author Dayanara Torres Launches Online Asthma Education Resource for Hispanic Community in Partnership with Merck and AAFA 6Trinity Orthopedics Receives Patent Allowance for Sagittally Stable Spinal Fixation System 2
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
(Date:7/29/2014)... According to a July 22, 2014 ... “From Kim’s Butt to Angelina’s Lips: The Plastic Surgery ... the celebrity feature most requested by women seeking cosmetic ... Jennifer Lawrence’s nose, and Angelina Jolie’s ... data collected by an online community focused on plastic ...
(Date:7/29/2014)... York, New York (PRWEB) July 29, 2014 ... on behalf of individuals who allegedly suffered serious ... medications continue to move forward in a multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... revised certain deadlines pertaining to bellwether case ...
(Date:7/29/2014)... 2014 Avenidas is always looking ... Once again, the non-profit agency is doing just that with ... seniors. , This event gives seniors the opportunity to learn ... There will be a variety of fun activities, including a ... demonstrations and artists. In addition, there will be food tastings, ...
(Date:7/29/2014)... Virginia Commonwealth University School of Medicine researchers have ... against the debilitating and potentially deadly tick-transmitted disease, ... several years, experts have seen a steady rise ... tick-transmitted bacterial pathogens making the need for ... knowing what to target to prevent disease, and ...
Breaking Medicine News(10 mins):Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: Federal Court Overseeing Tylenol Liver Damage Claims Sets New Deadlines Pertaining to Discovery, Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3
... ALEXANDRIA, Va., Oct. 8 The National,Community Pharmacists ... two-term incumbent representing Illinois, for re-election to the,U.S. ... CEO of NCPA,issued the following statement:, "Senator ... and,America,s community pharmacies and the patients they serve. ...
... Pharmacists Association (NCPA) is endorsing Sen. Gordon Smith,(R-OR), ... the,U.S. Senate. Bruce Roberts, RPh, executive vice president ... "Senator Gordon Smith is a powerful advocate for ... serve. That is why the National,Community Pharmacists Association ...
... Inc. (OTCPK:,SNDY) is pleased to announce that the Company ... ending June 30, 2008. Revenues,generated through the first six-months ... comparable period in 2007. The Company,saw an increase in ... just,over $8,000 at the end of fiscal year 2007., ...
... are no safe substitutes for authentic,FDA approved injectables, ... and counterfeit cosmetic injectables are a threat to ... for Injectable Safety. "The,growing acceptance of cosmetic injections ... with consumer cautions," says Coalition,leader, plastic surgeon Jeffrey ...
... Extreme heat events (EHE), or heat waves, are the ... United States, responsible for more deaths annually than hurricanes, ... other climate-related changes in the worldwide environment that directly ... of the American Journal of Preventive Medicine . ...
... Kong Celebrates a Wealth of Innovative Products, HONG ... leader in,research and development, announces today that it will ... 2008 at Gordon Wu Hall, B P,International House to ... in 1902 in Minnesota, United States, 3M has an ...
Cached Medicine News:Health News:Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com 2Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Climate change will affect public health -- a call to action 2Health News:Climate change will affect public health -- a call to action 3Health News:3M Innovation Day 2Health News:3M Innovation Day 3
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
Medicine Products: